
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Medlab Announces Favourable Interim Readout of Nanabis Real-World Evidence (RWE) Medcare Study
Details : NanaBis™ (tetrahydrocannabinol) is an investigative novel analgesic for cancer patients comprising equal parts of CBD and THC encapsulated in Medlab’s patented delivery platform, NanoCelle®. NanaBis™ is applied to the oro-buccal membrane for rapid...
Product Name : NanaBis
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Macquarie University
Deal Size : Undisclosed
Deal Type : Collaboration
Government Grant to Apply NanoCelle® to an RNA Nasal Vaccine
Details : This Government Grant & Academic collaboration solidify Medlab’s transition to a true Biotech company. The NanoCelle® non-invasive nasal delivered vaccine is considered a “first in class” medicine delivery system.
Product Name : NanoCelle
Product Type : Vaccine
Upfront Cash : Undisclosed
January 14, 2022
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Macquarie University
Deal Size : Undisclosed
Deal Type : Collaboration

Details : Delta 9 Tetrahydrocannabinol is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cancer Pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 22, 2021
